New Delhi, Jan. 21 -- Hyderabad-based Dr Reddy's Laboratories beat street estimates in the third quarter, reporting revenue of Rs.8,726.8 crore and profit after tax (PAT) of Rs.1,210 crore, with steady India growth and favourable forex helping offset the loss of Revlimid sales in the US.

A Bloomberg poll of 24 and 22 brokerages had pegged the drugmaker's consolidated revenue at Rs.8,338 crore and its profit after tax at Rs.1,089 crore, respectively.

The firm's revenue grew nearly 4.4% year-on-year (y-o-y) but marginally declined sequentially by 0.9%, while its profit after tax was down 14% y-o-y, and 16% quarter-on-quarter (q-o-q), as product-specific headwinds persisted.

Its Earnings Before Interest, Taxes, Depreciation, and Amortizat...